anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Cisatracurium
Trial phase: Phase 3
ATC code: M03AC04 | M03AC11
SMILES: COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 501
Group description: Patients will receive cisastracurium besylate for the first 48 hours of the trial.

cisastracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisastracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.
Eligibility criteria:
Inclusion Criteria

Age > 18 years

Presence of all of the following conditions for < 48 hours:

i. PaO2/FiO2 < 150 with PEEP >/= 8 cm H2O OR, if ABG not available, SaO2/FiO2 ratio that is equivalent to a PaO2/FiO2 < 150 with PEEP >/= 8 cm H2O , and a confirmatory SaO2/FiO2 ratio that is again equivalent 1-6 hours later

ii. Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules.

iii. Respiratory failure not fully explained by cardiac failure or fluid overload; need objective assessment (e.g., echocardiography) to exclude hydrostatic edema if no risk factor present.

Patients must be enrolled within 48 hours of meeting inclusion criteria.

Exclusion Criteria:

Lack of informed consent
Continuous neuromuscular blockade at enrollment
Known pregnancy
Currently receiving ECMO therapy
Chronic respiratory failure defined as PaCO2 > 60 mm Hg in the outpatient setting
Home mechanical ventilation (non-invasive ventilation or via tracheotomy) except for CPAP/BIPAP used solely for sleep-disordered breathing
Actual body weight exceeding 1 kg per centimeter of height
Severe chronic liver disease defined as a Child-Pugh score of 12-15 (Appendix A2)
Bone marrow transplantation within the last 1 year
Expected duration of mechanical ventilation of < 48 hours
Decision to withhold life-sustaining treatment; except in those patients committed to full support except cardiopulmonary resuscitation if an actual cardiac arrest occurs
Moribund patient not expected to survive 24 hours; if CPR provided, assess for moribund status greater than 6 from CPR conclusion
Diffuse alveolar hemorrhage from vasculitis
Burns > 70% total body surface
Unwillingness to utilize the ARDS Network 6 ml/kg IBW ventilation protocol
Previous hypersensitivity or anaphylactic reaction to cisatracurium
Neuromuscular conditions that may potentiate neuromuscular blockade and/or impair spontaneous ventilation (Appendix A2)
Neurologic conditions undergoing treatment for intracranial hypertension
Enrollment in an interventional ARDS trial with direct impact on neuromuscular blockade and PEEP
>120 hours of mechanical ventilation
P/F < 200 mmHg at the time of randomization (if available)
Intervention: Ketorolac
Trial phase: Phase 4
ATC code: M01AB15 | S01BC05 | S01FB51
SMILES: O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 70
Group description: Patients in this arm will be given ketorolac at cord clamp with standard dose of 30 mg, then 3 additional 30 mg doses every 6 hours

Ketorolac: Patients in the experimental arm will receive ketorolac 30 mg in 1 ml at the time of cord clamp and then for 3 more doses every 6 hours.
Eligibility criteria:
Inclusion Criteria:

Patients undergoing a scheduled or non-scheduled, non-urgent primary or repeat Cesarean delivery between 37-42 weeks gestational age,
Viable singleton intra-uterine pregnancy,
Patients undergoing a scheduled or unscheduled, non-emergent/non-urgent Cesarean delivery for placenta previa or vasa previa,
Neuraxial anesthesia with combined spinal-epidural placed for surgery,
Patients must be 18 years or older as well as willing and able to provide informed consent.

Exclusion Criteria:

Patients unable or unwilling to provide informed consent,
Urgent or emergent Cesarean delivery
Multiple fetal gestations (>1 intrauterine pregnancy),
Cesarean delivery for bleeding such as placental abruption or actively bleeding placenta previa or vasa previa,
Contraindication to NSAID use eg: allergy, chronic renal disease,
Patients with acute or chronic platelet dysfunction (e.g.: idiopathic thrombocytopenic purpura, HELLP syndrome),
Platelets <100k,
History of peptic ulcer disease,
Inherited or acquired coagulopathies or bleeding disorder, (disseminated intravascular coagulopathy, hemophilia),
Suspected or proven placenta accreta, increta or percreta,
Inability to receive epidural morphine,
Diagnosed chronic pain disorder on chronic adjunct or opioid analgesia,
Use of general anesthesia during procedure.

Intraoperative exclusion criteria:

- EBL > 1000 ml prior to cord clamp
Intervention: Medroxyprogesterone acetate
Trial phase: Phase 4
ATC code: G03AA08 | G03AA17 | G03AC06 | G03DA02 | G03FA12 | G03FB06 | L02AB02
SMILES: [H][C@@]12C[C@H](C)C3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@@]1(C)[C@@]2([H])CC[C@]1(OC(C)=O)C(C)=O
Sex: Female
Age groups: Child | Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 401
Group description: Subjects who are randomized to self-administration will be taught self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA sc) by a clinic nurse or other qualified personnel using instructions based on the packaging insert. If willing, subjects will then self-administer DMPA sc under supervision. Subjects who are able to correctly self-administer DMPA sc as assessed by the supervising nurse and who are interested in continued home self-administration will then be provided medication (3 doses of DMPA sc), a self-administration kit (includes alcohol swabs, cotton pads, bandages, mini sharps disposal container), and instructions to do so for the subsequent 3 injections indicating the appropriate dates for injection. All subjects will receive reminders when their next injection is due.

Subcutaneous depot medroxyprogesterone acetate: Based on study arm, subjects will either be taught to self-inject or will be administered DMPA sc by qualified clinic personnel.
Eligibility criteria:
Inclusion Criteria:

Females ages 15-44
Current or past users of DMPA or desires initiation of DMPA for contraception
Can understand spoken and written English or Spanish
Willing to consider/attempt DMPA self-injection
Willing to be randomized to either self- or clinic administration of DMPA
Do not want to become pregnant in the next 12 months
Willing to provide contact information and to complete three surveys at baseline, 6 months, and 12 months
Have consistent access to a working telephone, email, and Internet
No contraindications to DMPA use

Exclusion Criteria:

Suspected or confirmed pregnancy
Vaginal bleeding of unknown etiology
Known or suspected breast cancer
Acute liver disease
High blood pressure (Systolic ≥ 160 mm Hg or diastolic ≥ 100 mm Hg)
Known hypersensitivity to medroxyprogesterone acetate or any other components of DMPA
Desire for pregnancy within one year
Intervention: Medroxyprogesterone acetate
Trial phase: Phase 4
ATC code: G03AA08 | G03AA17 | G03AC06 | G03DA02 | G03FA12 | G03FB06 | L02AB02
SMILES: [H][C@@]12C[C@H](C)C3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@@]1(C)[C@@]2([H])CC[C@]1(OC(C)=O)C(C)=O
Sex: Female
Age groups: Child | Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 401
Group description: Subjects who are randomized to clinic administration will receive subcutaneous depot medroxyprogesterone acetate (DMPA sc) injection administered by a clinic nurse or other qualified personnel and receive standard care. They will be instructed to make an appointment to return to the clinic as usual to receive subsequent injections every 12-14 weeks. All subjects will receive reminders when their next injection is due.

Subcutaneous depot medroxyprogesterone acetate: Based on study arm, subjects will either be taught to self-inject or will be administered DMPA sc by qualified clinic personnel.
Eligibility criteria:
Inclusion Criteria:

Females ages 15-44
Current or past users of DMPA or desires initiation of DMPA for contraception
Can understand spoken and written English or Spanish
Willing to consider/attempt DMPA self-injection
Willing to be randomized to either self- or clinic administration of DMPA
Do not want to become pregnant in the next 12 months
Willing to provide contact information and to complete three surveys at baseline, 6 months, and 12 months
Have consistent access to a working telephone, email, and Internet
No contraindications to DMPA use

Exclusion Criteria:

Suspected or confirmed pregnancy
Vaginal bleeding of unknown etiology
Known or suspected breast cancer
Acute liver disease
High blood pressure (Systolic ≥ 160 mm Hg or diastolic ≥ 100 mm Hg)
Known hypersensitivity to medroxyprogesterone acetate or any other components of DMPA
Desire for pregnancy within one year
Intervention: Revefenacin
Trial phase: Phase 3
ATC code: R03BB08
SMILES: CN(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)C(=O)c1ccc(CN2CCC(C(N)=O)CC2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 205
Group description: 88 mcg

TD-4208
Eligibility criteria:
Inclusion Criteria:

Subject is a male or female subject 40 years of age or older

Exclusion Criteria:

Females who are pregnant, lactating, breast-feeding or planning to become pregnant during the study
Intervention: Revefenacin
Trial phase: Phase 3
ATC code: R03BB08
SMILES: CN(CCN1CCC(OC(=O)Nc2ccccc2-c2ccccc2)CC1)C(=O)c1ccc(CN2CCC(C(N)=O)CC2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 197
Group description: 175 mcg

TD-4208
Eligibility criteria:
Inclusion Criteria:

Subject is a male or female subject 40 years of age or older

Exclusion Criteria:

Females who are pregnant, lactating, breast-feeding or planning to become pregnant during the study
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 38
Group description: Bupivacaine as a parasternal nerve block following pediatric cardiothoracic surgery

Bupivacaine: Bupivacaine will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:

Under 20kgs weight: 0.25% Bupivacaine at 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5% Bupivacaine at 0.5 ml/kg up to a maximum of 25ml of 0.5% Bupivacaine for patients > 50 kgs
Eligibility criteria:
Inclusion Criteria:

Age 0-17 years old at time of surgery
Society of Thoracic Surgeons- European Association for Cardio-Thoracic Surgery (STAT) mortality categories 1-3
Surgical intervention requiring median sternotomy
Expected extubation within 24 hours of surgery

Exclusion Criteria:

Known allergic reaction or hypersensitivity to Bupivacaine or to any local anesthetic agent of the amide type
Delayed sternum closure
Intervention: Chlorotrianisene
Trial phase: Phase 2
ATC code: G03CA06
SMILES: COc1ccc(C(Cl)=C(c2ccc(OC)cc2)c2ccc(OC)cc2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 32
Group description: Participants with HCC with a lesion greater than 3 cm treated with TACE/SBRT combination.

SBRT: Radiation is to be delivered to 30-45 Gy in 5 fractions. 40 Gy in 5 fractions will be utilized, unless dose constraints preclude it. Treatment will optimally be delivered every other day with no more than 3 fractions per week. The ideal treatment team will be less than 15 total days.

TACE: two sessions of standard TACE with ethiodol separated by a 4-week interval.
Eligibility criteria:
Inclusion Criteria:

Participants must be diagnosed with HCC either pathologically or by the American Association for the Study of Liver Diseases (AASLD) radiographic criteria (Bruix Hepatology 2011). The criteria specifies CT or MRI intense arterial uptake followed by "washout" of contrast in the venous-delayed phases. Any atypical lesions must be confirmed by biopsy.
A single liver lesion with tumor size ≥ 3 cm as defined as maximal diameter in the axial dimension on MRI. Included in the measurement are both enhancing and non-enhancing components of the lesion.
Maximum tumor size of 7 cm as defined as maximal diameter in the axial dimension on MRI.
Age ≥ 18 years
Child-Pugh class A or B7 without ascites
ECOG score 0
No prior treatment of current HCC. However, recurrent HCC after resection may be included.
Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

Pregnancy which will be assessed via pregnancy test prior to TACE and repeated prior to SBRT.
Metastatic disease outside of the liver
Vascular invasion as evidenced by vessel occlusion or radiographic evidence of tumor thrombus.
Contraindications to MRI, including claustrophobia, metallic implants, and pacemakers
Tumor for which adequate radiation dosage cannot be safely delivered (see dose constraints below)
Prior therapeutic radiation therapy to the abdomen and/or lower thorax as defined as below the carina to the pelvic inlet.
Inability to provide informed consent based on persistent lack of understanding, inability to find adequate translation, impaired mental status such as mental retardation, drug induced, or traumatic brain injury.
Multiple liver tumors making the patient a BCLC Stage B
Prior treatment, except for surgical resection, to the lesion being targeted in the protocol.
Intervention: Bupivacaine
Trial phase: Phase 2
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 37
Group description: Stellate Ganglion Block injection with bupivacaine

Bupivicaine: A computer-generated 1:1 block randomization scheme will be used to assign participants to receive bupivacaine. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
Eligibility criteria:
Inclusion Criteria:

aged 30 to 70 years
28 or more reported moderate-to-very severe hot flashes per week
a minimum of two weeks of VMS diary recording prior to SGB
current use of tamoxifen, aromatase inhibitors, or SERMs for a breast cancer indication for at last six months
willingness to undergo fluoroscopy-guided SGB or sham treatment.
Approval of healthcare provider if ≥ 21 for depression and ≥15 for anxiety on the Depression Anxiety and Stress Scale (DASS)
Stable use of Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs) if applicable

Exclusion Criteria:

conditions that preclude SGB or sham intervention (e.g., anatomic abnormalities of the anterior neck or cervical spine; goiter, cardiac/pulmonary compromise; acute illness/infection; coagulopathy or bleeding disorder; allergic reactions/contraindications to a local anesthetic or contrast dye);
use of treatments in the past two months that can affect VMS (e.g., use of oral or transdermal Hormone Treatment (HT) or contraceptives, SERMS,
conditions or disorders that can affect performance on cognitive tests (e.g., dementia/mild cognitive impairment; stroke; traumatic brain injury; alcohol/substance use; inability to write, speak, or read in English, English as a second language
Mini-Mental State Exam (MMSE) ≥ 28
conditions that can affect sleep quality (e.g., use of sleep agents; shift work; etc.)
Intervention: SODIUM CHLORIDE
Trial phase: Phase 2
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 37
Group description: Saline injection

Saline: A computer-generated 1:1 block randomization scheme will be used to assign participants to receive saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
Eligibility criteria:
Inclusion Criteria:

aged 30 to 70 years
28 or more reported moderate-to-very severe hot flashes per week
a minimum of two weeks of VMS diary recording prior to SGB
current use of tamoxifen, aromatase inhibitors, or SERMs for a breast cancer indication for at last six months
willingness to undergo fluoroscopy-guided SGB or sham treatment.
Approval of healthcare provider if ≥ 21 for depression and ≥15 for anxiety on the Depression Anxiety and Stress Scale (DASS)
Stable use of Selective Serotonin Reuptake Inhibitors (SSRIs), Selective Norepinephrine Reuptake Inhibitors (SNRIs) if applicable

Exclusion Criteria:

conditions that preclude SGB or sham intervention (e.g., anatomic abnormalities of the anterior neck or cervical spine; goiter, cardiac/pulmonary compromise; acute illness/infection; coagulopathy or bleeding disorder; allergic reactions/contraindications to a local anesthetic or contrast dye);
use of treatments in the past two months that can affect VMS (e.g., use of oral or transdermal Hormone Treatment (HT) or contraceptives, SERMS,
conditions or disorders that can affect performance on cognitive tests (e.g., dementia/mild cognitive impairment; stroke; traumatic brain injury; alcohol/substance use; inability to write, speak, or read in English, English as a second language
Mini-Mental State Exam (MMSE) ≥ 28
conditions that can affect sleep quality (e.g., use of sleep agents; shift work; etc.)
Intervention: CID 12303048
Trial phase: Not Applicable
ATC code: S03AA04
SMILES: NC(=NCCCCCCN=C(N)N=C(N)Nc1ccc(Cl)cc1)N=C(N)Nc1ccc(Cl)cc1.O=C(O)C(O)C(O)C(O)C(O)CO.O=C(O)C(O)C(O)C(O)C(O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 20
Group description: Subjects will be randomized to twice daily chlorhexidine gluconate mouthwash for 21 days.

Chlorhexidine gluconate: Chlorhexidine gluconate is a germicidal mouthwash that reduces bacteria in the mouth.
Eligibility criteria:
Inclusion Criteria:

Age >18
Scheduled for upper endoscopy for clinical indications
No allergy or other contraindication to chlorhexidine

Exclusion Criteria:

Use of proton pump inhibitors or H2 receptor antagonists within 1 month of enrollment. Acid suppressant medications raise the gastric pH and can dramatically alter the gastric and esophageal microbiome.
History of upper gastrointestinal cancer
History of histologically proven Barrett's esophagus
History of antireflux or bariatric surgery, or other gastric or esophageal surgery
Use of antimicrobial mouthwash within 1 month of enrollment
Use of antibiotics or immunosuppressant medications within 3 months of enrollment
Use of steroid inhalers or nasal sprays within 1 month of enrollment
HIV or other immunosuppressed states or conditions (e.g. active malignancy)
Pregnant or breast feeding
Inability to give informed consent
Intervention: Ketamine
Trial phase: Phase 2 | Phase 3
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Participants will receive subcutaneous ketamine (1mg/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections at a dose of 1mg/kg.

Ketamine: Patients will receive a subcutaneous injection of ketamine (at a dose of 1mg/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.

Ketamine participants had more hallucinations than saline group.
Eligibility criteria:
Inclusion Criteria:

- All patients undergoing upper abdominal, thoracic, gynecologic or orthopaedic surgeries during a one month period with expected post operative hospital admission

Exclusion Criteria:

Allergy to Ketamine
History of narcotic abuse or dependence
Those patients for which decreased cognitive function is a barrier to accurate data collection
Intervention: SODIUM CHLORIDE
Trial phase: Phase 2 | Phase 3
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Participants will receive subcutaneous saline (0.02cc/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.

Saline: Patients will receive a subcutaneous injection of saline (at a dose of 0.02cc/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
Eligibility criteria:
Inclusion Criteria:

- All patients undergoing upper abdominal, thoracic, gynecologic or orthopaedic surgeries during a one month period with expected post operative hospital admission

Exclusion Criteria:

Allergy to Ketamine
History of narcotic abuse or dependence
Those patients for which decreased cognitive function is a barrier to accurate data collection
Intervention: Hematoporphyrin
Trial phase: Phase 3
SMILES: CC1=C(CCC(=O)O)c2cc3nc(cc4[nH]c(cc5[nH]c(cc1n2)c(C)c5C(C)O)c(C)c4C(C)O)C(C)=C3CCC(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 142
Group description: Participants applied IDP-122 Lotion (HP 0.01%) topically once daily for 8 weeks.
Eligibility criteria:
Key Inclusion Criteria:

Male or female, of any race, at least 18 years of age (inclusive).
Freely provides both verbal and written informed consent.
Has an area of plaque psoriasis appropriate for topical treatment that covers a body surface area (BSA) of at least 3%, but no more than 12%. The face, scalp, palms, soles, axillae, and intertriginous areas are to be excluded in this calculation.
Is willing and able to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural and artificial) for the duration of the study.
Has a clinical diagnosis of psoriasis at the Baseline visit with an IGA score of 3 or 4 (the face, scalp, palms, soles, axillae, and intertriginous areas are to be excluded from this calculation, if psoriasis is present).

Key Exclusion Criteria:

Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular psoriasis, as determined by the Investigator.
Presents with psoriasis that was treated with prescription medication and failed to respond to treatment, even partially or temporarily, as determined by the Investigator.
Presents with any concurrent skin condition that could interfere with the evaluation of the treatment areas, as determined by the Investigator.
Is pregnant, nursing an infant, or planning a pregnancy during the study period.
Has received treatment with any investigational drug or device within 60 days or 5 drug half-lives (whichever is longer) prior to the Baseline visit or is concurrently participating in another clinical study with an investigational drug or device.